• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket

    4/11/24 6:14:41 AM ET
    $ACOR
    $ADIL
    $ALLR
    $ALPN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACOR alert in real time by email

    Shares of Rallybio Corporation (NASDAQ:RLYB) rose sharply in today’s pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.

    Rallybio shares jumped rose 77.9% to $2.90 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Rent the Runway, Inc. (NASDAQ:RENT) shares rose 40.8% to $10.42 in pre-market trading after the company reported mixed fourth-quarter financial results and issued guidance.
    • Alpine Immune Sciences, Inc. (NASDAQ:ALPN) gained 36.1% to $64.02 in pre-market trading after Vertex entered into an agreement to acquire the company.
    • TuanChe Limited (NASDAQ:TC) shares gained 24.4% to $2.24 in pre-market trading after falling 8% on Wednesday.
    • Verb Technology Company, Inc. (NASDAQ:VERB) gained 18.5% to $0.2156 in pre-market trading after gaining 4% on Wednesday.
    • Vera Therapeutics, Inc. (NASDAQ:VERA) climbed 13.1% to $47.06 in pre-market trading after gaining 10% on Wednesday.
    • BitFuFu Inc. (NASDAQ:FUFU) shares gained 12.5% to $4.90 in pre-market trading after reporting full year 2023 financial results.
    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) rose 10.2% to $3.56 in pre-market trading after dipping 10% on Wednesday.
    • CuriosityStream Inc. (NASDAQ:CURI) gained 10.8% to $1.58 in pre-market trading after surging over 10% on Wednesday. Curiosity Stream, on March 20, reported mixed fourth-quarter financial results.
    • SciSparc Ltd. (NASDAQ:SPRC) shares rose 8.3% to $1.82 in pre-market trading.


    Losers

    • Aptevo Therapeutics Inc. (NASDAQ:APVO) fell 31.3% to $1.65 in pre-market trading. Aptevo Therapeutics recently issued pipeline update.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) fell 17.7% to $0.7158 in pre-market trading after declining 14% on Wednesday. Acorda Therapeutics recently commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code.
    • ClearOne, Inc. (NASDAQ:CLRO) declined 17.1% to $0.9046 in pre-market trading. The company recently reported fourth-quarter financial results.
    • SolarBank Corporation (NASDAQ:SUUN) fell 14.4% to $4.98 in pre-market trading. SolarBank closed purchase of 3.15 MW solar project in New York from Storke Renewable.
    • Meiwu Technology Company Limited (NASDAQ:WNW) shares declined 13.4% to $1.15 in pre-market trading after jumping around 32% on Wednesday.
    • Novo Integrated Sciences, Inc. (NASDAQ:NVOS) fell 12.7% to $0.4452 pre-market trading after declining around 4% on Wednesday.
    • iCoreConnect Inc. (NASDAQ:ICCT) shares fell 9.5% to $1.53 in pre-market trading after jumping over 50% on Wednesday.
    • Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) shares fell 9.3% to $2.11 in pre-market trading. Adial Pharmaceuticals shares jumped 106% on Wednesday after the company announced the publication of a peer-reviewed article highlighting the clinical results, strong safety profile, and high compliance among patients administered AD04.
    • Nyxoah S.A. (NASDAQ:NYXH) fell 8.3% to $9.74 in pre-market trading.
    • AVITA Medical, Inc. (NASDAQ:RCEL) fell 4.2% to $13.83 pre-market trading after the company announced an update to its expected commercial revenue for the first quarter of 2024.

     

    Now Read This: Jim Cramer Says WESCO International Is A Buy, Recommends Buying This Stock Under $20

     

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $ADIL
    $ALLR
    $ALPN

    CompanyDatePrice TargetRatingAnalyst
    Vera Therapeutics Inc.
    $VERA
    3/11/2026$88.00Peer Perform → Outperform
    Wolfe Research
    Avita Medical Inc.
    $RCEL
    3/5/2026$10.00Outperform
    Northland Capital
    Avita Medical Inc.
    $RCEL
    11/20/2025Sell → Neutral
    BTIG Research
    Vera Therapeutics Inc.
    $VERA
    10/16/2025$48.00Buy
    BofA Securities
    CuriosityStream Inc.
    $CURI
    8/18/2025$7.00Buy
    Craig Hallum
    BitFuFu Inc.
    $FUFU
    8/13/2025$6.00Buy
    Roth Capital
    Avita Medical Inc.
    $RCEL
    8/8/2025$3.00Neutral → Sell
    BTIG Research
    Vera Therapeutics Inc.
    $VERA
    8/4/2025Outperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $ACOR
    $ADIL
    $ALLR
    $ALPN
    SEC Filings

    View All

    Vera Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

    3/9/26 5:01:12 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    3/9/26 9:02:24 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Rallybio Corporation

    SCHEDULE 13G/A - Rallybio Corp (0001739410) (Subject)

    3/6/26 10:12:33 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADIL
    $ALLR
    $ALPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vera Therapeutics upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Vera Therapeutics from Peer Perform to Outperform and set a new price target of $88.00

    3/11/26 8:30:17 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Northland Capital initiated coverage on Avita Medical with a new price target

    Northland Capital initiated coverage of Avita Medical with a rating of Outperform and set a new price target of $10.00

    3/5/26 8:30:26 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Avita Medical upgraded by BTIG Research

    BTIG Research upgraded Avita Medical from Sell to Neutral

    11/20/25 7:57:06 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $ACOR
    $ADIL
    $ALLR
    $ALPN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner First Finance Ltd. bought $1,750,000 worth of shares (437,500 units at $4.00), increasing direct ownership by 36% to 1,641,162 units (SEC Form 4)

    4 - CLEARONE INC (0000840715) (Issuer)

    3/6/26 6:02:39 AM ET
    $CLRO
    Telecommunications Equipment
    Utilities

    CFO O'Toole David D bought $12,450 worth of shares (3,000 units at $4.15), increasing direct ownership by 2% to 140,127 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    2/23/26 4:30:08 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Director Enright Patrick G bought $249,985 worth of shares (5,882 units at $42.50) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    12/15/25 8:07:34 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADIL
    $ALLR
    $ALPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Fmr Llc claimed ownership of 211,798 shares (SEC Form 3)

    3 - Rallybio Corp (0001739410) (Issuer)

    3/10/26 1:24:15 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hite Christopher

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    3/9/26 4:49:21 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Hite Christopher

    3 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    3/9/26 4:47:13 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADIL
    $ALLR
    $ALPN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

    TEL AVIV, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a definitive share purchase agreement (the "SPA"), between NeuroThera, CliniQuantum Ltd. ("CliniQ") and the Selling Shareholders (as defined below) to acquire approximately 54.01% of the issued and outstanding ordinary shares of CliniQ (the "CliniQ Shares") on a fully diluted basis immediately prior to the closing

    3/10/26 9:28:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

    Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed $200 billion by 2035 Vancouver, Canada, March 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT)

    3/10/26 8:59:00 AM ET
    $CMND
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rent the Runway Appoints Dhiren Fonseca as Executive Chairman

    NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Rent the Runway, Inc. ("Rent the Runway" or the "Company") (NASDAQ:RENT), the company that is transforming the way women get dressed, today spotlights the appointment of Dhiren Fonseca as Executive Chairman of the Board of Directors, who has served since October 2025. Fonseca is a seasoned business leader with a distinguished track record of scaling high-growth technology and consumer companies. His extensive experience spans private equity, travel, and digital commerce, making him uniquely positioned to guide Rent the Runway as it continues to innovate its platform, deepen its supplier relationships, and explore strategic partnerships. "Dhire

    3/9/26 9:15:00 AM ET
    $RENT
    Other Specialty Stores
    Consumer Discretionary

    $ACOR
    $ADIL
    $ALLR
    $ALPN
    Leadership Updates

    Live Leadership Updates

    View All

    Rent the Runway Appoints Dhiren Fonseca as Executive Chairman

    NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Rent the Runway, Inc. ("Rent the Runway" or the "Company") (NASDAQ:RENT), the company that is transforming the way women get dressed, today spotlights the appointment of Dhiren Fonseca as Executive Chairman of the Board of Directors, who has served since October 2025. Fonseca is a seasoned business leader with a distinguished track record of scaling high-growth technology and consumer companies. His extensive experience spans private equity, travel, and digital commerce, making him uniquely positioned to guide Rent the Runway as it continues to innovate its platform, deepen its supplier relationships, and explore strategic partnerships. "Dhire

    3/9/26 9:15:00 AM ET
    $RENT
    Other Specialty Stores
    Consumer Discretionary

    Vera Therapeutics Appoints Christopher Hite to Board of Directors

    BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christopher Hite, an accomplished executive with decades of corporate and financial strategy leadership experience in the biopharmaceutical sector, to Vera Therapeutics' Board of Directors. "It is a pleasure to welcome Chris to our Board of Directors at this exciting juncture in Vera Therapeutics' trajectory as we near the potential launch of our first-in-class dual BAFF/APRIL inhibitor for patients with IgA nephropathy," sa

    3/5/26 9:00:22 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

    BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. "We are pleased to welcome Matt to the executive team as we prepare for the potential commercial launch of atacicept for the treatment of IgA nephropathy," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "With his track record

    1/28/26 7:30:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADIL
    $ALLR
    $ALPN
    Financials

    Live finance-specific insights

    View All

    Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

    Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 Mont-Saint-Guibert, Belgium – March 5 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and full year of 2025 on Thursday, March 19, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or

    3/5/26 4:05:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

    Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed and upsized financing of over $505 million committed by a syndicate of leading healthcare institutional investors and mutual funds expected to fund operations through 2030 Companies to hold joint conference call on March 2, 2026 at 8:30 AM ET Rallybio Corporation (NASDAQ:RLYB) ("Rallybio") and Candid Therapeutics, Inc. ("Candid"), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager ("TCE") therapeutics for autoimmune diseases, today announced that they have entered into

    3/2/26 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results

    VALENCIA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights and Recent Business Updates Total revenue of $17.6 million, compared to $18.4 million in the fourth quarter of 2024, reflecting the lingering impact of reimbursement headwinds throughout 2025.Gross profit margin of 81.2%, reflecting product mix and inventory-related adjustments.Net use of cash improved for the second consecutive quarter t

    2/12/26 4:01:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $ACOR
    $ADIL
    $ALLR
    $ALPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by iCoreConnect Inc.

    SC 13G/A - iCoreConnect Inc. (0001906133) (Subject)

    12/12/24 9:44:00 PM ET
    $ICCT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by iCoreConnect Inc.

    SC 13G/A - iCoreConnect Inc. (0001906133) (Subject)

    12/5/24 4:08:58 PM ET
    $ICCT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Verb Technology Company Inc.

    SC 13G/A - Verb Technology Company, Inc. (0001566610) (Subject)

    11/15/24 8:24:57 PM ET
    $VERB
    Other Consumer Services
    Consumer Discretionary